172 related articles for article (PubMed ID: 33752313)
1. [Analysis of clinical characteristics and prognosis of 235 pancreatic neuroendocrine tumors underwent Sunitinib treatment].
Xu JM; Cui HT; Jia R; Zhao CH; Zhao P
Zhonghua Zhong Liu Za Zhi; 2021 Mar; 43(3):324-328. PubMed ID: 33752313
[No Abstract] [Full Text] [Related]
2. Comparison of Tumor Markers for Predicting Disease-Free Survival in Surgically Resected Pancreatic Neuroendocrine Tumors.
Zhou B; Fang B; Yan S; Wang W
Clin Lab; 2017 Jul; 63(7):1251-1259. PubMed ID: 28792692
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological characteristics and prognosis-related factors of resectable pancreatic neuroendocrine tumors: a retrospective study of 104 cases in a single Chinese center.
Han X; Xu X; Jin D; Wang D; Ji Y; Lou W
Pancreas; 2014 May; 43(4):526-31. PubMed ID: 24658317
[TBL] [Abstract][Full Text] [Related]
4. A retrospective cohort study of pancreatic neuroendocrine tumors at single institution over 15 years: New proposal for low- and high-grade groups, validation of a nomogram for prognosis, and novel follow-up strategy for liver metastases.
Ye L; Ye H; Zhou Q; Li Z; Lin Q; Tan L; Gao W; Fu Z; Zheng S; Chen R
Int J Surg; 2016 May; 29():108-17. PubMed ID: 27000717
[TBL] [Abstract][Full Text] [Related]
5. Functionality is not an independent prognostic factor for pancreatic neuroendocrine tumors.
Chen HY; Zhou YL; Chen YH; Wang X; Zhang H; Ke NW; Liu XB; Tan CL
World J Gastroenterol; 2020 Jul; 26(25):3638-3649. PubMed ID: 32742132
[TBL] [Abstract][Full Text] [Related]
6. Maximum Value on Arterial Phase Computed Tomography Predicts Prognosis and Treatment Efficacy of Sunitinib for Pancreatic Neuroendocrine Tumours.
Chen H; Li Z; Hu Y; Xu X; Ye Z; Lou X; Zhang W; Gao H; Qin Y; Zhang Y; Chen X; Chen J; Tang W; Yu X; Ji S
Ann Surg Oncol; 2023 May; 30(5):2988-2998. PubMed ID: 36310316
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcome and long-term survival of 150 consecutive patients with pancreatic neuroendocrine tumors: A comprehensive analysis by the World Health Organization 2010 grading classification.
Deng BY; Liu F; Yin SN; Chen AP; Xu L; Li B
Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):261-268. PubMed ID: 29307515
[TBL] [Abstract][Full Text] [Related]
8. Sunitinib malate as first-line treatment for an advanced, poorly differentiated pancreatic neuroendocrine tumor.
Lin LZ; Li P; Chen HR; Pang LJ
Future Oncol; 2013 Jun; 9(6):909-13. PubMed ID: 23718311
[TBL] [Abstract][Full Text] [Related]
9. Observational Study in a Real-World Setting of Targeted Therapy in the Systemic Treatment of Progressive Unresectable or Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors (pNETs) in France: OPALINE Study.
Smith D; Lepage C; Vicaut E; Dominguez S; Coriat R; Dubreuil O; Lecomte T; Baudin E; Venat Bouvet L; Samalin E; Santos A; Borie O; Bisot-Locard S; Goichot B; Lombard-Bohas C
Adv Ther; 2022 Jun; 39(6):2731-2748. PubMed ID: 35419649
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors in 151 patients with surgically resected non-functioning pancreatic neuroendocrine tumours.
Song KB; Kim SC; Kim JH; Hong SM; Park KM; Hwang DW; Lee JH; Lee YJ
ANZ J Surg; 2016 Jul; 86(7-8):563-7. PubMed ID: 25040037
[TBL] [Abstract][Full Text] [Related]
11. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
[TBL] [Abstract][Full Text] [Related]
12. Real-world use of sunitinib in Japanese patients with pancreatic neuroendocrine tumors: results from a post-marketing surveillance study.
Sato K; Toyoshima Y; Moriyama S; Endo Y; Ito T; Ohki E
Cancer Chemother Pharmacol; 2019 Jan; 83(1):201-207. PubMed ID: 30413868
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological features and long-term prognosis of purely cystic pancreatic neuroendocrine tumors: A single-center experience.
Ren SJ; Wang X; Ke NW; Tan QQ; Yang F; Yao WQ; Tan CL; Liu XB
Asian J Surg; 2023 Feb; 46(2):774-779. PubMed ID: 35850904
[TBL] [Abstract][Full Text] [Related]
14. An update on the management of pancreatic neuroendocrine tumors.
Gao L; Natov NS; Daly KP; Masud F; Chaudhry S; Sterling MJ; Saif MW
Anticancer Drugs; 2018 Aug; 29(7):597-612. PubMed ID: 29782352
[TBL] [Abstract][Full Text] [Related]
15. Resection of the primary pancreatic neuroendocrine tumor in patients with unresectable liver metastases: possible indications for a multimodal approach.
Bertani E; Fazio N; Botteri E; Chiappa A; Falconi M; Grana C; Bodei L; Papis D; Spada F; Bazolli B; Andreoni B
Surgery; 2014 Apr; 155(4):607-14. PubMed ID: 24582492
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of the preoperative main pancreatic duct dilation and neutrophil-to-lymphocyte ratio in pancreatic neuroendocrine tumors (PNETs) of the head after curative resection.
Zhou B; Zhan C; Xiang J; Ding Y; Yan S
BMC Endocr Disord; 2019 Nov; 19(1):123. PubMed ID: 31718651
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors of long-term outcome in surgically resectable pancreatic neuroendocrine tumors: A 12-year experience from a single center.
Zhou B; Duan J; Yan S; Zhou J; Zheng S
Oncol Lett; 2017 Mar; 13(3):1157-1164. PubMed ID: 28454228
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic targeting of tumor-associated macrophages in pancreatic neuroendocrine tumors.
Krug S; Abbassi R; Griesmann H; Sipos B; Wiese D; Rexin P; Blank A; Perren A; Haybaeck J; Hüttelmaier S; Rinke A; Gress TM; Michl P
Int J Cancer; 2018 Oct; 143(7):1806-1816. PubMed ID: 29696624
[TBL] [Abstract][Full Text] [Related]
19. A single institution's 21-year experience with surgically resected pancreatic neuroendocrine tumors: an analysis of survival and prognostic factors.
Cienfuegos JA; Rotellar F; Salguero J; Ruiz-Canela M; Núñez Córdoba JM; Sola I; Benito A; Martí-Cruchaga P; Zozaya G; Pardo F; Hernández Lizoáin JL
Rev Esp Enferm Dig; 2016 Nov; 108(11):689-696. PubMed ID: 27701882
[TBL] [Abstract][Full Text] [Related]
20. Surveillance and comparison of surgical prognosis for asymptomatic and symptomatic non-functioning pancreatic neuroendocrine tumors.
Ge W; Zhou D; Xu S; Wang W; Zheng S
Int J Surg; 2017 Mar; 39():127-134. PubMed ID: 28137555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
